Skip to main content

Table 2 Values of fixed effects and variabilities for the final model of 4 biomarkers without covariates

From: Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model

Fixed effects

Estimates

RSE (%)

P-value

C0F ( μg/L)

598

8

 

C0C (nmol/h.mL)

7920

11

 

C0H (g/dL)

11.6

1

 

C0P (/mm3)

74300

4

 

  exp(β_ splen)

2.5

8

< 10−10

rF

0.4

8

 

rC

0.1

14

 

rH

1.2

1

 

rP

2.1

4

 

  exp(β_ splen)

0.5

19

10−7

k (years−1)

1.4

10

 

Variabilities

   

  ω_ C0F

83

8

 

  ω_C0C

120

7

 

  ω_ C0H

13

6

 

  ω_C0P

42

6

 

  ω_rF

67

9

 

  ω_rC

117

10

 

  ω_rH

10

10

 

  ω_rP

31

10

 

  ω_k

90

10

 

  σ_F

30

4

 

  σ_C

61

4

 

  σ_H

7

2

 

  σ_P

20

3

 
  1. C0 is initial concentration, r amplitude of variation and k the rate of normalization during ERT. F corresponds to ferritin, C to chitotriosidase, H to hemoglobin and P to platelets. The P-value is for the Wald test. Exp β represents the effect of the covariates. Splen corresponds to the covariate splenectomy. ω: standard deviation of inter-individual variability, σ: standard deviation of proportional residual error. RSE: relative standard error. For example, baseline ferritin concentration is C0F =598 μg/L, and the estimated corrected value at steady state of ERT is C0F × r F  =  179.4 μg/L. Baseline platelet count in non-splenectomized patients is C0P =  74,300/mm3 and C0P exp(β _ splen) = 185,750 /mm3 in splenectomized patients. The estimated corrected platelet count at steady state of ERT in splenectomized patients is (C0P × exp(β _ splen)) × (r0 × exp(β _ splen)) = 195,037 /mm3.